Eptifibatide: The evidence for its role in the management of acute coronary syndromes

References

• Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation. 1988;77:526–534.
   PubMed Web of Science ®Google Scholar
• Couté S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med. 1995;46:257–265.
   PubMed Web of Science ®Google Scholar
• Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(3 Suppl):II38– II46.
   Web of Science ®Google Scholar
• Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, editors. The heart and cardiovascular system: scientific foundations. 2nd ed. New York: Raven Press; 1992. p. 219–273.
   Google Scholar
• DeWood MA, Spores, Jnotske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902.
   PubMed Web of Science ®Google Scholar
• Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31:301–311.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost. 2003;1:1602–1612.
   PubMed Web of Science ®Google Scholar
• Bennett JS. Platelet-fibrinogen interactions. Ann NY Acad Sci. 2001;936:340–354.
   PubMed Web of Science ®Google Scholar
• Schafer AI. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Tex Heart Inst J. 1997;24:90–96.
   PubMed Web of Science ®Google Scholar
• BHF (British Heart Foundation) statistics website. Available at: http://www.heartstats.org/datapage.asp?id=1584 (accessed August 25, 2007).
   Google Scholar
• Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction 2002. Summary article: a report of the American College of cardiology/American Heart Association Task force on Practice Guidelines (Committee on the management of Patient With Unstable Angina). Circulation. 2002;106:1893–1900.
   PubMed Web of Science ®Google Scholar
• Silber S, Albertsson R, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–847.
   PubMed Web of Science ®Google Scholar
• Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119(Suppl 1):321S–336S.
   PubMed Web of Science ®Google Scholar
• McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002;88:711–715.
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–3175.
   PubMed Web of Science ®Google Scholar
• Peterson ED, Pollack CV Jr, Roe MT, et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST elevation acute myocardial infarction observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol. 2003:42:45–53.
   PubMed Web of Science ®Google Scholar
• Hoekstra JW, Roe MT, Peterson ED, et al. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005;2:431–438.
   Google Scholar
• Schrör K, Weber AA. Comparative pharmacology of Gp IIb/IIIa antagonists. J Thromb Thrombolysis. 2003:15:71–80.
   Google Scholar
• EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956–961.
   PubMed Web of Science ®Google Scholar
• Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifibatide in healthy subjects receiving unfractionated heparin or the low-molecular weight heparin enoxaparin. Clin Ther. 2003;25:2564–2574.
   PubMed Web of Science ®Google Scholar
• Lev EI, Hasdai D, Scapa E, et al. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or the unfractionated heparin: effect on platelet function or thrombus formation. J Am Coll Cardiol. 2004;43:966–971.
   PubMed Web of Science ®Google Scholar
• Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002;143:585–593.
   PubMed Web of Science ®Google Scholar
• Saucedo JF, Aude W, Pacheco R, et al. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). Am J Cardiol. 2005;95:1453–1456.
   PubMed Web of Science ®Google Scholar
• Dalby M, Montalescot G, Bal dit Solier C, et al. Eptifibatide provides additional platelet inhibition in non-ST elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43:162–168.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153–1159.
   PubMed Web of Science ®Google Scholar
• Brener SJ, Zeymer U, Adgey AAJ, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial Infarction (INTRO AMI) trial. J Am Coll Cardiol. 2002;39:377–386.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Roe MT, Harrington RA, et al; INTEGRITI Investigators. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic Trial. J Am Coll Cardiol. 2003;41:1251–1260.
   PubMed Web of Science ®Google Scholar
• Rebeiz AG, Johanson P, Green CL, et al. Comparison of ST segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005;95:611–614.
   PubMed Web of Science ®Google Scholar
• Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndrome. Circulation. 2001;103:1727–1733.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Easton D, Harrington RA, et al; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406.
   PubMed Web of Science ®Google Scholar
• Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet. 2002;359:189–198.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation. 1999;99:2371–2377.
   PubMed Web of Science ®Google Scholar
• Scarborough RM. Development of eptifibatide. Am Heart J. 1999;138:1093–1104.
   PubMed Web of Science ®Google Scholar
• Gilchrist IC. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokineticpharmakodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42:703–720.
   PubMed Web of Science ®Google Scholar
• Lorenz TJ, Macdonald F, Kitt MM. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb–IIIa. Clin Ther. 1999;21:128–137.
   PubMed Web of Science ®Google Scholar
• Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997;95:846–854.
   PubMed Web of Science ®Google Scholar
• Tardiff BE, Jennings LK, Harrington RA, et al; PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001;104:399–405.
   PubMed Web of Science ®Google Scholar
• Tcheng JE, Talley JD, O’Shea JC, et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol. 2001;88:1097–1102.
   PubMed Web of Science ®Google Scholar
• Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. 1999;57:439–462.
   PubMed Web of Science ®Google Scholar
• Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80:11B–20B.
   PubMed Web of Science ®Google Scholar
• Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb/IIIa interaction with integrilin: enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488–1494.
   PubMed Web of Science ®Google Scholar
• Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol. 1997;80:34B–38B.
   Web of Science ®Google Scholar
• PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443.
   PubMed Web of Science ®Google Scholar
• ESPRIT investigators. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet. 2000;356:2037–2044.
   PubMed Web of Science ®Google Scholar
• Fischell TA, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol. 2006;18:487–491.
   PubMedGoogle Scholar
• IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II integrilin to minimise platelet aggregation and coronary thrombosis-II. Lancet. 1997;349:1422–1428.
   PubMed Web of Science ®Google Scholar
• Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; the INTERACT Trial Long-Term Follow-Up Investigators. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J. 2006;151:373–379.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Fitchett DH, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high risk patients with non-ST-segment elevation acute coronary syndromes receiving the GP IIb/IIIa receptor inhibitor eptifibatide. Circulation. 2003:107;238–244.
   PubMed Web of Science ®Google Scholar
• Ronner E, van Kesteren HAM, Zijnen P, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: a phase II dose escalation, randomized, double-blind study. Eur Heart J. 2000;21:1530–1536.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Cove C, Irons D, et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol. 2001;88:A6, 62–64.
   PubMed Web of Science ®Google Scholar
• Zeymer U, Zahn R, Schiele R, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005;26:1971–1977.
   PubMed Web of Science ®Google Scholar
• Gibson M, Kirtane AJ, Murphy SA, et al; TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J. 2006;152:668–675.
   PubMed Web of Science ®Google Scholar
• PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J. 2001;141:402–409.
   PubMed Web of Science ®Google Scholar
• Wong DH. Comparison of eptifibatide and abciximab with decision analysis. Am J Health Syst Pharm. 2001;58:1432–1436.
   PubMed Web of Science ®Google Scholar
• Burgess BC, Hanna-Moussa S, Ramasamy K, et al. Abciximab or eptifibatide in percutaneous coronary intervention: in-hospital outcomes and costs and six-month results. Int J Angiol. 2002;11:221–224.
   Google Scholar
• McCallum PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm. 2003;60:1251–1256.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Ibbotson T. Spotlight on eptifibatide in percutaneous coronary intervention and acute coronary syndromes. Disease Management and Health Outcomes. 2004:12;207–210.
   Google Scholar
• Cohen DJ, O’Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Am J Cardiol. 2002:89;61–64.
   PubMedGoogle Scholar
• Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 1995;91: 2151–2157.
   PubMed Web of Science ®Google Scholar
• O’Shea JC, Hafley GE, Greenberg S, et al; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285:2468–2473.
   PubMed Web of Science ®Google Scholar
• Suleiman M, Gruberg L, Hammerman H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol. 2003;15:319–323.
   PubMedGoogle Scholar
• Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation. 2000;101:751–757.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2000;102:1093–1100.
   PubMed Web of Science ®Google Scholar
• Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002;105:322–327.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bhatt DL, Roe MT, et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. Circulation. 2000;102:2952–2958.
   PubMed Web of Science ®Google Scholar
• Anon. Eptifibatide: summary of product characteristics. 2007. Available at www.emea.eu.int/humandocs/Humans/EPAR/Integrilin/Integrilin.htm.
   Google Scholar
• Anon. Integrilin® Prescribing information. Cambridge, MA, and Kenilworth, NJ. Millenium Pharmaceuticals Inc and Schering Corporation, 2005.
   Google Scholar
• Atwater BD, Roe MT, Mahaffey KW. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. Drugs. 2005;65:313–324.
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Schühlen H, et al; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627–3635
   PubMed Web of Science ®Google Scholar
• Schömig A, Schmitt C, Dibra A, et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. One year outcomes with abciximab vs placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J. 2005;26:1379–1384.
   PubMed Web of Science ®Google Scholar
• Leopold JA, Antman EM. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Circulation. 2005;111: 1097–1099.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847–853.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Kleiman NS, et al; REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomaxto Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092–1096.
   PubMed Web of Science ®Google Scholar
• Brouse SD, Wiesehan VG. Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors. Ann Pharmacother. 2004;38:1783–1788.
   PubMed Web of Science ®Google Scholar
• Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905–1914.
   PubMed Web of Science ®Google Scholar
• ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–613.
   Google Scholar
• CLEAR Investigators. The combined approach to lysis utilizing eptifibatide and Rt-PA (CLEAR) stroke trial, tier 1 interval safety results. Ann Emerg Med. 2005;46(Suppl):121.
   Google Scholar